Lynparza (olaparib) — Medica

Initial criteria

• age ≥ 18 years
• metastatic castration resistant prostate cancer
• EITHER used concurrently with a gonadotropin-releasing hormone (GnRH) analog OR patient has had a bilateral orchiectomy
• ONE of the following: (1) germline or somatic homologous recombination repair (HRR) gene-mutated disease confirmed by an approved test AND previously treated with at least one androgen receptor-directed therapy OR (2) BRCA mutation AND used in combination with abiraterone plus prednisone or prednisolone

Approval duration

1 year